(LMAT) (WKN: A0LB2B)


Seite 1 von 1
Neuester Beitrag: 28.06.20 17:07
Eröffnet am:30.10.15 15:47von: TamakoschyAnzahl Beiträge:15
Neuester Beitrag:28.06.20 17:07von: TamakoschyLeser gesamt:7.355
Forum:Börse Leser heute:3
Bewertet mit:
1


 

3324 Postings, 5165 Tage Tamakoschy(LMAT) (WKN: A0LB2B)

 
  
    #1
1
30.10.15 15:47
Business Summary


Designs and manufactures vascular devices for vascular surgeons

LeMaitre Vascular, Inc. is a medical device company, which provides innovative devices for the treatment of peripheral vascular disease.

The company develops, manufactures and markets disposable and implantable vascular devices to address the needs of vascular surgeons.

Its products line include the following: balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy.

LeMaitre Vascular was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.



http://www.4-traders.com/...5329/?type_recherche=rapide&mots=lmat

http://seekingalpha.com/article/...rnings-call-transcript?part=single

 

3324 Postings, 5165 Tage TamakoschyUnternehmensseite: Zahlen

 
  
    #2
31.10.15 11:50


http://ir.lemaitre.com/phoenix.zhtml?c=198313&p=irol-newsLeMaitre


Q3 2015 Sales $19.0mm (+12% organic), Record Op. Inc. $3.3mm (+79%)

BURLINGTON, Mass., Oct. 27, 2015 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, today reported Q3 2015 results, announced a $0.04/share dividend and provided guidance.

Q3 2015 results included:
•Sales of $19.0mm, +9% reported (+12% organic) vs. Q3 2014
•Record operating income of $3.3mm vs. $1.9mm, +79%
•Record operating margin of 17%
•Record net income of $2.1mm vs. $0.9mm, +124%
•Earnings of $0.11 per diluted share vs. $0.05, +115%
•Record EBITDA of $4.0mm vs. $2.7mm, +47%
•Cash increased $4.2mm to $23.6mm




 

3324 Postings, 5165 Tage Tamakoschy15 % plus nach Q2 Zahlen

 
  
    #3
28.07.16 18:50

3324 Postings, 5165 Tage TamakoschyWieder starke Zahlen Q3 16

 
  
    #4
27.10.16 18:58

3324 Postings, 5165 Tage Tamakoschymisses Street 4Q forecasts

 
  
    #5
22.02.17 16:56

3324 Postings, 5165 Tage TamakoschyUnterstüzung bei 22 hat gehalten

 
  
    #6
13.04.17 16:25
Anstehende Termine für LEMAITRE VASCULAR INC
02/05/17

Q1 2017 Ergebnisveröffentlichung (geplant)
01/08/17

Erstes Halbjahr 2017 Ergebnisveröffentlichung (geplant)
31/10/17

Q3 2017 Ergebnisveröffentlichung (geplant)
27/02/18

Jahr 2017 Ergebnisveröffentlichung (geplant)  

3324 Postings, 5165 Tage Tamakoschy26.04.17 kkommen Q1 Zahlen

 
  
    #7
22.04.17 09:50
LeMaitre Vascular Will Announce First Quarter 2017 Earnings Results on April 26, 2017

http://www.4-traders.com/...rnings-Results-on-April-26-2017-24203367/  

3324 Postings, 5165 Tage TamakoschyZahlen verfehlt - abwärts geht es

 
  
    #11
26.04.18 21:18

3324 Postings, 5165 Tage TamakoschySA Artikel

 
  
    #12
26.04.18 21:22
LeMaitre Q1 top line up 8%; earnings up 20%; EPS guidance raised; shares down 17% on softer sales guidance
Apr. 26, 2018 10:05 AM ET|About: LeMaitre Vascular, Inc. (LMAT)|By: Douglas W. House, SA News Editor

Thinly traded small cap LaMaitre Vascular (LMAT -16.5%) is down on more than double normal volume, albeit on turnover of only 331K shares, in response to its Q1 results and softer sales guidance.

Q1 results: sales: $26.0M (+8%), net income: $3.9M (+20%); EPS: $0.19 (+17%).

2018 Guidance: Sales: $106.0M - 109.0M from $110.0M - 111.6M; EPS: $1.05 - 1.13 from $0.96 - 1.00.
https://seekingalpha.com/news/...ps-guidance-raised-shares-17-percent  

11554 Postings, 2480 Tage VassagoRARE 62,63$ (+10%)

 
  
    #13
20.02.19 16:28

Zahlen für 2018

  • Umsatz 51 Mio. $
  • Loss from operations 371 Mio. $
  • Cash 460 Mio $
  • Equity 609 Mio. $
  • Total Assets 720 Mio. $
  • MK 3,2 Mrd. $

http://ir.ultragenyx.com/news-releases/...nd-full-year-2018-financial


 

3324 Postings, 5165 Tage TamakoschyQ4 und Jahreszahlen

 
  
    #14
12.02.20 18:57
https://www.marketscreener.com/...itre-4Q-Earnings-Snapshot-29955227/
https://www.marketscreener.com/...Q4-2019-Financial-Results-29954359/

LeMaitre: 4Q Earnings Snapshot

02/06/2020 | 05:27pm EST
BURLINGTON, Mass. (AP) _ LeMaitre Vascular Inc. (LMAT) on Thursday reported fourth-quarter net income of $4.6 million.
On a per-share basis, the Burlington, Massachusetts-based company said it had net income of 23 cents.
The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for earnings of 23 cents per share.
The medical device maker posted revenue of $30.2 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $30.5 million.
For the year, the company reported profit of $17.9 million, or 88 cents per share. Revenue was reported as $117.2 million.
For the current quarter ending in April, LeMaitre expects its per-share earnings to range from 14 cents to 17 cents.
The company said it expects revenue in the range of $30.5 million to $31.7 million for the fiscal first quarter.
LeMaitre expects full-year earnings in the range of 90 cents to 98 cents per share, with revenue ranging from $127.4 million to $130.8 million.
 

3324 Postings, 5165 Tage TamakoschyLeMaitre Vascular Acquires Artegraft

 
  
    #15
28.06.20 17:07
https://www.marketscreener.com/...scular-Acquires-Artegraft-30807335/

06/22/2020 | 09:13pm BST
BURLINGTON, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that it has acquired the business and assets of Artegraft, Inc. for $90.0 million, including $72.5 million in cash paid at closing ($65.0 million to Artegraft plus $7.5 in escrow to be released December 31, 2021) as well as potential earnout payments of $17.5 million payable based upon future sales of the acquired business.  Under the terms of the deal, LeMaitre will continue to operate Artegraft’s manufacturing facility in North Brunswick, NJ for at least three and a half years and will retain most of Artegraft’s employees, including seven sales & marketing personnel.

Q1:
https://www.marketscreener.com/...itre-1Q-Earnings-Snapshot-30509209/  

   Antwort einfügen - nach oben